UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
MARCH 12, 2002
------------------
(Date of earliest event reported)


LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Exact name of registrant as specified in its charter)


   DELAWARE                1-11353             13-3757370
 --------------          -----------         --------------
(State or other         (Commission          (IRS Employer
jurisdiction of         File Number)         Identification
incorporation)                                   Number)


358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
-------------------------------------------------------
(Address of principal executive offices)

336-229-1127
------------
(Registrant's telephone number, including area code)




ITEM 9. Regulation FD Disclosure.

   Laboratory Corporation of America -Registered Trademark-
Holdings (LabCorp -Registered Trademark-)(NYSE:LH) announced
that Bradford T. Smith, executive vice president of public
affairs, is scheduled to speak at the SG Cowen Annual
Healthcare Conference in Boston on Wednesday, March 13 at
1:15 p.m. Eastern Time.

At the conference, Mr. Smith will reiterate Company guidance
for 2002, as filed in an 8-K on February 13. Mr.Smith will
state,  "For 2002, we expect revenue growth of 12 percent
compared to 2001, EBITDA margins of approximately 23 percent
of sales and EPS growth of approximately 33 percent compared
to 2001, before applying the new accounting rules regarding
goodwill effective January 1, 2002.  After applying the new
accounting rules, we expect the non-amortization of goodwill
to have an impact of approximately $26 million in 2002,
resulting in an increase to EPS of approximately $0.36."

Each of the above forward-looking statements is subject to
change based on various important factors, including without
limitation, competitive actions in the marketplace and
adverse actions of governmental and other third-party
payors.  Further information on potential factors that could
affect LabCorp's financial results is included in the
Company's Form 10-K for the year ended December 31, 2001 and
subsequent SEC filings.




SIGNATURES

Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.

          LABORATORY CORPORATION OF AMERICA HOLDINGS
          ------------------------------------------
                        (Registrant)

               By:/s/ BRADFORD T. SMITH
                  ----------------------------------
                      Bradford T. Smith
                      Executive Vice President
                      and Secretary



Date:March 12, 2002